Connect with us

Business

Eli Lilly Ends Coronavirus Antibody Treatment Trial, Other Studies Go On – NPR

The trial studied the efficacy of bamlanivimab and remdesivir on hospitalized COVID-19 patients – the same therapies given to President Trump. But researchers say…

Published

on

post featured image

In this May 2020 file photo provided by Eli Lilly, a researcher tests possible COVID-19 antibodies in a laboratory in Indianapolis. On Monday, U.S. government officials announced they are putting an early end to a study testing an Eli Lilly antibody drug for people hospitalized with COVID-19 because it doesn’t seem to help.
David Morrison/AP
Eli Lilly & Co. is ending a clinical trial of its antibody drug in hospitalized COVID-19 patients after federal researchers concluded the therapy doesn’t work…

Click here to view the original article.